Esperion Therapeutics (ESPR) Research & Development (2012 - 2026)

Esperion Therapeutics has reported Research & Development for 15 years, with the latest figure at $9.0 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 28.42% year-over-year to $9.0 million; the trailing twelve-month figure through Mar 2026 stood at $44.3 million (down 2.44% YoY), and the FY2025 full-year result was $47.9 million, up 3.49% from the prior year.
• Research & Development for Q1 2026 stood at $9.0 million, down from $13.9 million in the prior quarter.
• The five-year high for Research & Development was $33.0 million in Q4 2022, with the low at $7.2 million in Q2 2025.
• Historically, Research & Development has averaged $18.1 million across 5 years, with a median of $14.1 million in 2025.
• Annual changes were most pronounced in 2024 — Research & Development sank 57.29% — and 2025, when it soared 35.91%.
• Esperion Therapeutics' Research & Development stood at $33.0 million in 2022, then slumped by 46.29% to $17.7 million in 2023, then slumped by 38.13% to $11.0 million in 2024, then climbed by 26.87% to $13.9 million in 2025, then tumbled by 35.46% to $9.0 million in 2026.
• The last three Research & Development figures came in at $9.0 million (Q1 2026), $13.9 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.